Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer
Helsinki, Finland – April 9, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced a collaboration with PlusVitech, a biotechnology company developing treatments for cancer, to use Nanoform’s state-of-the-art nanomedicine technology to repurpose the anti-nausea medicine aprepitant as a treatment for lung cancer. The development program will include nanoforming the current active ingredient into…